Poolbeg Pharma: What US Payers Really Said
Episode 2411 · Jun 03, 06:17 AM
Share
Subscribe
Watch on YouTube
Independent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.